| 发明名称 | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis | ||
| 摘要 | The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject. | ||
| 申请公布号 | US9399061(B2) | 申请公布日期 | 2016.07.26 |
| 申请号 | US200711786442 | 申请日期 | 2007.04.10 |
| 申请人 | ABBVIE BIOTECHNOLOGY LTD | 发明人 | Kupper Hartmut;Kent Jeffrey D.;Cifaldi Mary A.;Perez John L.;Burmester Gerd R.;Mease Philip;Lovell Daniel J.;Keystone Edward;Kavanaugh Arthur |
| 分类号 | A61K39/00;A61K39/395;A61K39/39;C07K16/24;A61K39/09;A61K39/145;C12N7/00 | 主分类号 | A61K39/00 |
| 代理机构 | Foley Hoag LLP | 代理人 | Foley Hoag LLP |
| 主权项 | 1. A method for treating an adult patient having moderate to severe active rheumatoid arthritis (RA), wherein the patient is nonresponsive to treatment with etanercept and infliximab, the method comprising administering 40 mg of adalimumab to the patient every other week to thereby treat the moderate to severe active RA. | ||
| 地址 | Hamilton BM | ||